Danaher Diagnostics — Capital expenditures, gross increased by 24.2% to $195.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 16.1%, from $168.00M to $195.00M. Over 2 years (FY 2023 to FY 2025), Diagnostics — Capital expenditures, gross shows relatively stable performance with a 4.1% CAGR.
Higher spending suggests investment in growth or maintenance, while very low spending may indicate under-investment in the business.
The total cash outflow for the acquisition or maintenance of physical assets, such as manufacturing machinery and labora...
Standard metric for capital-intensive manufacturing and life science firms.
dhr_segment_diagnostics_capital_expenditures_gross| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $136.50M | $136.50M | $136.50M | $136.50M | $127.00M | $126.00M | $129.00M | $168.00M | $115.00M | $125.00M | $157.00M | $195.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.0% | -0.8% | +2.4% | +30.2% | -31.5% | +8.7% | +25.6% | +24.2% |
| YoY Change | — | — | — | — | -7.0% | -7.7% | -5.5% | +23.1% | -9.4% | -0.8% | +21.7% | +16.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.